drugset / Trial / NCT01618474
Trial of Adjuvant Chemotherapy for High Risk Gastric Cancer Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial is going to evaluate the efficacy and safety of two regimens of DX (docetaxel plus capecitabine)and XELOX (oxaliplatin plus capecitabine)as adjuvant chemotherapy for stage IIIb-IIIc gastric cancer patients after curative D2/D2+ operation, and to investigate the optimal adjuvant regimen for such extremely high risk patients.
Timeline
- Start
- 2012-05
- Primary completion
- 2016-11
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
| Background | Capecitabine | Small molecule | 1000 mg/m2 | Oral |